| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
36,651,000 |
| Market
Cap: |
570.29(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$11.84 - $28.66 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quanterix is a life sciences company that has developed digital immunoassay platforms. Co.'s platforms are based on its proprietary digital Simoa detection technology. Co. provides the following three Simoa instruments: HD-X, which is based on Co.'s bead-based technology, and assays run on the HD-X are fully automated; SR-X, which utilizes the same Simoa bead-based technology and assay kits as the HD-X in a compact benchtop form with a range of applications; and SP-X, which is based on Co.'s planar array technology, which allows for multiplexing capabilities for oncology and immunology applications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
20,200 |
639,331 |
| Total Buy Value |
$0 |
$0 |
$501,978 |
$6,053,841 |
| Total People Bought |
0 |
0 |
1 |
7 |
| Total Buy Transactions |
0 |
0 |
1 |
8 |
| Total Shares Sold |
2,500 |
5,000 |
5,000 |
10,265 |
| Total Sell Value |
$60,025 |
$119,770 |
$119,770 |
$214,084 |
| Total People Sold |
1 |
1 |
1 |
5 |
| Total Sell Transactions |
2 |
4 |
4 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fry John J |
General Counsel & Secretary |
• – – |
2022-01-03 |
4 |
S |
$41.91 |
$14,751 |
D/D |
(352) |
31,976 |
|
63% |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2022-01-03 |
4 |
OE |
$2.28 |
$106,704 |
D/D |
41,246 |
64,528 |
|
- |
|
| Mcconnell Sarah H |
|
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$11,875 |
D/D |
2,948 |
14,840 |
|
- |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2022-01-03 |
4 |
S |
$41.91 |
$155,683 |
D/D |
(3,715) |
890,386 |
|
63% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2022-01-03 |
4 |
S |
$41.91 |
$6,244 |
D/D |
(149) |
23,120 |
|
63% |
|
| Olson Laurie J |
|
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,668 |
7,208 |
|
- |
|
| Walt David R |
|
– • – |
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
2,668 |
1,281,312 |
|
- |
|
| Crandell Keith |
|
– • • |
2022-01-03 |
4 |
A |
$0.00 |
$13,020 |
D/D |
2,975 |
118,257 |
|
- |
|
| Duffy David C. |
SVP R&D and CTO |
• – – |
2021-12-29 |
4 |
AS |
$40.71 |
$67,864 |
D/D |
(1,667) |
23,282 |
|
-54% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-12-01 |
4 |
S |
$40.26 |
$14,222 |
D/D |
(353) |
38,344 |
|
30% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2021-12-01 |
4 |
S |
$40.26 |
$149,477 |
D/D |
(3,710) |
894,101 |
|
30% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-12-01 |
4 |
S |
$40.26 |
$14,101 |
D/D |
(350) |
32,328 |
|
30% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-12-01 |
4 |
S |
$40.26 |
$5,923 |
D/D |
(147) |
23,269 |
|
30% |
|
| Crandell Keith |
|
– • • |
2021-11-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,318 |
115,282 |
|
- |
|
| Crandell Keith |
|
– • • |
2021-11-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(290,250) |
0 |
|
- |
|
| Crandell Keith |
|
– • • |
2021-11-16 |
4 |
A |
$0.00 |
$0 |
D/D |
9,952 |
105,964 |
|
- |
|
| Crandell Keith |
|
– • • |
2021-11-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(310,000) |
113,003 |
|
- |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2021-11-10 |
4 |
AS |
$54.05 |
$275,897 |
D/D |
(5,000) |
897,811 |
|
-46% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-11-05 |
4 |
AS |
$57.25 |
$488,851 |
D/D |
(8,535) |
38,697 |
|
-52% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-11-05 |
4 |
OE |
$19.12 |
$204,928 |
D/D |
10,718 |
47,232 |
|
- |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-11-04 |
4 |
AS |
$57.00 |
$57 |
D/D |
(1) |
36,514 |
|
-49% |
|
| Mattoon Dawn |
Sr. VP, Diagnostics |
• – – |
2021-11-02 |
4 |
S |
$52.40 |
$17,518 |
D/D |
(333) |
36,515 |
|
51% |
|
| Fry John J |
General Counsel & Secretary |
• – – |
2021-11-02 |
4 |
S |
$52.40 |
$17,412 |
D/D |
(331) |
32,678 |
|
51% |
|
| Hrusovsky E Kevin |
Chairman and CEO |
• • – |
2021-11-02 |
4 |
S |
$52.40 |
$184,385 |
D/D |
(3,505) |
902,811 |
|
51% |
|
| Roskey Mark T. |
SVP, Strategic Partnerships |
• – – |
2021-11-02 |
4 |
S |
$52.40 |
$7,312 |
D/D |
(139) |
23,416 |
|
51% |
|
278 Records found
|
|
Page 3 of 12 |
|
|
0.03 (0.19%) 
